For those who may not follow the 340B drug
pricing program closely, what is the 340B rebate
issue and why is it receiving so much attention?
The 340B drug pricing program has always been built on upfront
discounts. Hospitals and other covered entities purchase outpatient
drugs at reduced prices, and those savings help support care for
patients with low incomes and those in rural communities.
The rebate issue involves proposals to replace that structure with a
backend system. Under a rebate model, hospitals would buy drugs
at full price — wholesale acquisition cost — and then submit
claims data to drug companies after dispensing. The drugmakers
would review those claims and decide on their own whether they
qualify for rebates and when they would make those payments.
This has drawn significant attention because it would fundamentally
change how the program has operated for more than 30 years.
Instead of predictable savings at the point of purchase, hospitals
would need to front the full cost of drugs and rely on a retrospective
process that introduces uncertainty, delays, and financial risk into
what has historically been a stable framework.
What are the key recent developments
at the federal level?
The biggest development has been the halt of a federal rebate pilot
that the Health Resources & Services Administration (HRSA) had
approved for certain pharmaceutical companies manufacturing
drugs that are subject to new Medicare Part D price caps.
A federal court issued a preliminary injunction blocking the pilot,
finding that the agency likely failed to properly consider significant
administrative and financial costs the program would impose on
covered entities.
After that decision, the government attempted to move forward
with the pilot during the appeals process but was unsuccessful and
ultimately dismissed its appeal. The administration has indicated
it will not proceed with that specific pilot as approved, which
was a significant development for hospitals concerned about the
immediate impact of rebates.
At the same time, the agency has indicated it is pursuing an even
broader rebate program through a new process. It issued both a
request for information and a separate data collection proposal
to solicit stakeholder feedback on how such a rebate model might
work and what burdens it would create. So 340B rebates could
soon resurface in a different form and in a bigger way.
What would a rebate model mean for
hospital pharmacy operations?
340B rebates would introduce both financial and administrative
challenges that represent a major shift from current practice.
Today, 340B hospitals and pharmacies can acquire drugs at 340B
prices and operate with a clear understanding of acquisition costs.
That predictability supports budgeting, inventory management,
and program oversight activities.
Under a rebate model, hospitals would need to purchase drugs at
full price and carry those costs while waiting for reimbursement.
For high-cost therapies, that could require significant working
capital and create real cash-flow pressures, particularly for
hospitals that already operate on thin margins.
There also would be new administrative demands layered on top
of existing responsibilities. Hospitals would need to collect and
submit detailed claims data to each drugmaker, track submissions
across multiple platforms, reconcile payments, and investigate
discrepancies. Each company could have different requirements,
timelines, and validation processes, which adds complexity and
increases the likelihood of errors.
On top of that, hospitals would need processes for handling denied
or delayed rebates. That could involve additional staff time, new
technology investments, and closer coordination across pharmacy,
finance, and compliance teams.
Why the
340B
Rebate
Debate
Matters
SUMMER 2026 I HEALTH SYSTEM • INFUSION
38
Contributed by Steven Miller,
Vice President of Pharmacy and
Education for 340B Health